Editorial: Treat to target in rheumatoid arthritis: Good for the joints as well as the heart?

Arthritis and Rheumatology

Volumn 67, Issue 6, 2015, Pages 1412-1415

  Nurmohamed, Michael T ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CANAKINUMAB; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL DISEASE ACTIVITY INDEX; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DYSLIPIDEMIA; EDITORIAL; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; HEART; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; JOINT; MORBIDITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; SCREENING; SMOKING; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COMPLICATION; IMMUNOLOGY; PATIENT CARE PLANNING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; METHOTREXATE; PATIENT CARE PLANNING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929853653     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39096     Document Type: Editorial

References (20)

1. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D., Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7.
2. Van Doornum S, McColl G, Wicks IP., Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? [review]. Arthritis Rheum 2002; 46: 862-73.
3. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al., Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009; 61: 1571-9.
4. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al., The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70: 929-34.
5. Libby P., Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008; 121 Suppl 1: S21-31.
6. Karpouzas GA, Malpeso J, Choi TY, Li D, Munoz S, Budoff MJ., Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis 2014; 73: 1797-804.
7. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al., EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31.
8. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F., Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
9. Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al., Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 670-5.
10. Ljung L, Askling J, Rantapaa-Dahlqvist S, Jacobsson L, for the ARTIS Study Group. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther 2014; 16: R127.
11. Dixon WG, Watson KD, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al, on behalf of the British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-12.
12. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al., The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 480-9.
13. Nurmohamed MT, Bao Y, Signorovitch J, Mulani PM, Furst DE., Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis. Ann Rheum Dis 2012; 71 Suppl 3: 52.
14. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, et al., Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015; 67:1449-55.
15. Aletaha D, Smolen J., The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 Suppl 39: S100-8.
16. Myasoedova E, Chandran A, Ilhan B, Major BT, Michet CJ, Matteson EL, et al., The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis 2015. E-pub ahead of print.
17. Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, et al., The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc 2015; 4: e001588.
18. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al., Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69: 1920-5.
19. Van den Hoek J, Boshuizen HC, Roorda LD, Tijhuis GJ, Nurmohamed MT, van den Bos T, et al., Mortality decreases in patients with rheumatoid arthritis: a 15-year prospective cohort study. Arthritis Rheumatol 2014; 66 Suppl: S903.
20. Solomon DH, Peters MJ, Nurmohamed MT, Dixon W., Motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis. Arthritis Rheum 2013; 65: 1675-83.